Modus Therapeutics AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.modustx.com
Clinical Trials
6
Active:2
Completed:3
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Modus Therapeutics AB
- Target Recruit Count
- 24
- Registration Number
- NCT03853421
- Locations
- 🇺🇸
Clinical Pharmacology of Miami (CPMI), Miami, Florida, United States
Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Modus Therapeutics AB
- Target Recruit Count
- 147
- Registration Number
- NCT02515838
- Locations
- 🇧🇭
Salmaniya Hospital, Kingdom of Bahrain, Manama, Bahrain
🇧🇭Salmaniya Medical Complex, Bahrain, Manama, Bahrain
🇯🇲Annotto Bay Hospital, Annotto Bay, Jamaica
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Phase 1
Terminated
- Conditions
- Malaria, Falciparum
- Interventions
- Drug: atovaquone/proquanil
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Modus Therapeutics AB
- Target Recruit Count
- 53
- Registration Number
- NCT01442168
- Locations
- 🇹🇭
Mae Ramat Hospital, Mae Ramat, Tak province, Thailand
🇹🇭Maesot General hospital, Mae Sot, Tak Province, Thailand
🇹🇭Hospital for Tropical Diseases, Bangkok, Thailand
News
No news found